Calithera Biosciences, Inc. (NASDAQ:CALA) Short Interest Down 12.1% in January
Calithera Biosciences, Inc. (NASDAQ:CALA) Short Interest Down 12.1% in January
Calithera Biosciences, Inc. (NASDAQ:CALA – Get Rating) was the recipient of a significant drop in short interest in January. As of January 31st, there was short interest totalling 366,600 shares, a drop of 12.1% from the January 15th total of 417,300 shares. Approximately 7.7% of the company's stock are sold short. Based on an average daily volume of 309,500 shares, the days-to-cover ratio is presently 1.2 days.
卡利瑟拉生物科學公司 (NASDAQ: 卡拉-獲取評級) 是一月份短期利益顯著下降的收件人.截至 1 月 31 日，短期利息共計 366,600 股，較一月十五日共 417,300 股股份下降 12.1%。約 7.7％ 的公司股票賣空。根據每日平均成交量為 309,500 股，日數佔覆蓋比率目前為 1.2 天。
Calithera Biosciences Price Performance
卡利瑟拉生物科學價格性能
CALA stock remained flat at $0.09 during midday trading on Thursday. The company had a trading volume of 104,173 shares, compared to its average volume of 564,955. The stock has a market capitalization of $440,491.50, a P/E ratio of 0.00 and a beta of 1.05. The company's fifty day simple moving average is $1.27 and its 200 day simple moving average is $2.40. Calithera Biosciences has a fifty-two week low of $0.07 and a fifty-two week high of $13.38.
星期四中午交易期間，卡拉股票保持平穩 0.09 美元。該公司的交易量為 104,173 股，相比於其平均交易量為 564,955 股。該股票的市值為 440,491.50 美元，市盈率為 0.00 美元，貝塔值為 1.05。該公司的五十天簡單移動平均線為 1.27 美元，其 200 天的簡單移動平均線為 2.40 美元。卡利瑟拉生物科學有五十兩周低點 $0.07 和五十二周高點 $13.38.
Calithera Biosciences (NASDAQ:CALA – Get Rating) last posted its quarterly earnings results on Monday, November 14th. The biotechnology company reported ($2.01) EPS for the quarter, missing analysts' consensus estimates of ($1.99) by ($0.02). Research analysts anticipate that Calithera Biosciences will post -8.62 EPS for the current year.
卡利瑟拉生物科學 (NASDAQ: 卡拉-獲取評級) 最後發布其季度收益業績週一, 11 月 14 日.該生物技術公司報告了本季度每股收益（2.01 美元），缺少分析師的共識估計為（$1.99）（0.02 美元）。研究分析師預計，卡利塞拉生物科學將在本年度發布 -8.62 每股盈利。
Insider Buying and Selling at Calithera Biosciences
內幕購買和銷售在卡利塞拉生物科學
In other news, Director Deepika Pakianathan sold 121,333 shares of Calithera Biosciences stock in a transaction that occurred on Friday, January 27th. The stock was sold at an average price of $0.39, for a total transaction of $47,319.87. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 6.60% of the company's stock.
在其他消息中，董事迪皮卡巴基斯坦人在 1 月 27 日（星期五）發生的交易中出售了 121,333 股卡利瑟拉生物科學股票。該股票以 0.39 美元的平均價格出售，總交易額為 47,319.87 美元。出售已在與證券交易委員會提交的文件中披露，該文件可通過以下方式獲得 這個鏈接。企業內部人士擁有公司股票的 6.60％。
Institutional Trading of Calithera Biosciences
卡利塞拉生物科學的機構交易
Several institutional investors and hedge funds have recently modified their holdings of the business. Renaissance Technologies LLC lifted its position in shares of Calithera Biosciences by 36.5% during the 1st quarter. Renaissance Technologies LLC now owns 1,853,500 shares of the biotechnology company's stock worth $749,000 after buying an additional 496,100 shares during the last quarter. Alyeska Investment Group L.P. bought a new position in Calithera Biosciences in the first quarter valued at about $404,000. Affinity Asset Advisors LLC bought a new position in Calithera Biosciences in the first quarter valued at about $404,000. Vanguard Group Inc. raised its position in Calithera Biosciences by 23.4% in the third quarter. Vanguard Group Inc. now owns 141,217 shares of the biotechnology company's stock valued at $415,000 after purchasing an additional 26,800 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its position in Calithera Biosciences by 143.2% in the first quarter. Goldman Sachs Group Inc. now owns 123,739 shares of the biotechnology company's stock valued at $50,000 after purchasing an additional 72,865 shares during the last quarter. 33.73% of the stock is currently owned by institutional investors.
一些機構投資者和對沖基金最近修改了他們對業務的持有情況。文藝復興時期技術有限責任公司在卡利塞拉生物科學股份的地位 36.5% 在第一季度.文藝復興技術有限責任公司現在擁有 1,853,500 生物技術公司的股票價值 $749,000 在上一個季度購買了 496,100 股後的股票。阿麗斯卡投資集團有限責任公司在第一季度收購了卡利瑟拉生物科學的新頭寸，價值約為 404,000 美元。親和資產顧問有限責任公司在第一季度收購了卡利塞拉生物科學的新位置，價值約為 404,000 美元。先鋒集團股份有限公司在第三季度提高了 23.4% 在卡利塞拉生物科學的地位。領航集團股份有限公司現在擁有該生物技術公司股票的 141,217 股股份，價值為 415,000 元，並於上一季度額外購入 26,800 股股份。最後, 高盛集團公司. 在第一季度提出了其在卡利塞拉生物科學的地位 143.2%.高盛集團在上一季度額外購買 72,865 股股票後，現在擁有該生物技術公司的 123,739 股股票，價值為 50,000 美元。33.73％ 的股票目前由機構投資者擁有。
Analyst Upgrades and Downgrades
分析師升級和降級
Several research analysts have weighed in on the company. StockNews.com assumed coverage on Calithera Biosciences in a research report on Wednesday. They set a "hold" rating on the stock. SVB Leerink cut Calithera Biosciences from an "outperform" rating to a "market perform" rating in a research report on Tuesday, November 15th. Finally, LADENBURG THALM/SH SH cut Calithera Biosciences from a "buy" rating to a "neutral" rating in a research report on Tuesday, November 15th.
一些研究分析師對該公司進行了稱重。Stocknews.com 在周三的一份研究報告中承擔了卡利瑟拉生物科學的報導。他們設置了股票的「持有」評級。SVB Leerink 削減卡利塞拉生物科學從「跑贏大市」評級為「市場表現」評級在週二的研究報告, 11 月 15 日.最後, 拉登堡塔爾姆/SH SH 削減卡利塞拉生物科學從「買」評級為「中性」評級在週二的研究報告, 11 月 15 日.
About Calithera Biosciences
關於卡利瑟拉生物科學
(Get Rating)
(取得評分)
Calithera Biosciences, Inc is a clinical-stage biopharmaceutical company, which focuses on discovering and developing small molecule drugs that target novel and critical metabolic pathways in tumor and cancer-fighting immune cells. It offers programs such as Pipeline, Glutaminase Inhibitor, and Arginase Inhibitor.
Calithera Biosciences, Inc 是一家臨床階段生物製藥公司，致力於發現和開發針對腫瘤和抗癌免疫細胞中新穎和關鍵代謝途徑的小分子藥物。它提供了程序，如管道, 谷氨酰胺酶抑制劑, 和精氨酸酶抑制劑.
Further Reading
進一步閱讀
- Get a free copy of the StockNews.com research report on Calithera Biosciences (CALA)
- Bloomin' Brands Blossoms After Raising The Dividend
- Zebra Technologies: A Reversal Is In Play
- Zoetis, Pet-Med Specialist, Double-Digit Earnings Growth Ahead
- The S&P 500: Don't Trust The Wave Of Bullish Sentiment
- Cisco Systems Is Ready To Run Higher
- 獲取有關卡利瑟拉生物科學研究報告的免費副本
- Bloomin' 品牌提高股息後綻放
- 斑馬科技：逆轉正在發揮作用
- Zoetis，寵物醫學專家，未來兩位數的盈利增長
- 標普 500：不要相信看漲情緒的浪潮
- 思科系統已準備好運作更高
Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接收卡利塞拉生物科學日報的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件時事通訊接收有關 Calithera 生物科學及相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。